ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

ProQR Therapeutics N.V.NASDAQ: PRQR

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of €705.41K rose 4.0% year over year, ahead of the -0.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 4.9% from the prior quarter. Over 3 fiscal years it compounded at +1.0% a year.

Context

  • Depreciation & amortization amounted to 17.0% of revenue in FY2025, up 2.4 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +4.0% holds above the trailing-twelve-month pace of -0.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€705.41K+4.9% QoQ
Last fiscal yearDec 2025
€2.6M-6.0% YoY
LTMMar 2026
€2.72M-0.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.0%——
1 year-6.0%——
3-year CAGR+1.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

EUR · from the cash flow

Latest · FY2025
2.6M EUR
Year-over-year change
-6.0%
4-year CAGR
+2.8%

Depreciation & Amortization vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.9% is the 6th highest of 11, against a peer median of +0.5%.
  • Depreciation & amortization amounts to 20.3% of revenue for PRQR, versus a peer median of 8.6%.
PRQR Competitors
Depreciation & Amortization for PRQR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$1.25B USD+83349.3%+52.5%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$12.13M USD-8.0%-4.7%—
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$8.66M USD+9.7%—4.0%
EDITEditas Medicine, Inc.LTM Mar 2026$4.17M USD-34.0%-5.9%10.8%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$2.88M USD-16.2%+25.6%6.4%
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.72M EUR-0.9%+1.0%20.3%
IMMPImmutep LimitedFY2025A$2.39M AUD+5.6%+5.0%47.4%
MREOMereo BioPharma Group plcLTM Mar 2026$1.18M USD+9.0%-11.2%236.0%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$284K USD-92.5%+29.3%4.9%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$223K USD-4.7%-1.1%—
ZURAZura Bio LimitedLTM Mar 2026$56K USD+229.4%——
Peer median (excluding PRQR) —+0.5%+1.9%8.6%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(60.8M)(64.2M)(27.74M)(27.76M)(40.52M)
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
Deferred Income Tax117K96K(78K)(197K)0
Stock-Based Compensation6.22M2.87M3.11M2.54M0
Change in Working Capital25.01M(4.99M)48.96M(13.26M)(16.73M)
Accounts Receivables00000
Inventory00000
Accounts Payables00000
Other Working Capital25.01M(4.99M)48.96M(13.26M)(16.73M)
Other Non-Cash Items1.11M(4.8M)(5.21M)(474K)3.94M
Operating Cash Flow(26.01M)(68.51M)21.55M(36.39M)(50.71M)
Capital Expenditures(484K)(708K)(1.37M)(1.42M)(979.75K)
Acquisitions (Net)00000
Purchases of Investments000(17M)0
Sales of Investments00017M0
Other Investing Activities59K6K5.65M(2.66M)0
Investing Cash Flow(425K)(702K)4.28M(4.07M)(979.74K)
Debt Repayment26.84M(45.05M)(2.63M)(1.58M)(1.91M)
Common Stock Issued108.48M14.12M071.64M66.28K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.52M34K354K223K75.19K
Financing Cash Flow136.83M(30.89M)(2.28M)70.28M(1.76M)
Effect of Forex Changes1.29M7.35M599K673K14.15M
Net Change in Cash111.69M(92.75M)24.15M30.48M(39.3M)
Free Cash Flow(26.5M)(69.22M)20.18M(37.81M)(51.69M)

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.